Tag: bioMérieux
bioMérieux: the stock rises, an analyst remains a buyer – 04/26/2024 at 5:39 p.m.
(CercleFinance.com) – The stock ended the session up more than 2%, benefiting from Berenberg’s positive analysis. The research office announced on Friday that it had raised bioMérieux from 114.5 to…
bioMérieux: the stock rises, an analyst remains a buyer
(CercleFinance.com) – The stock ended the session up more than 2%, benefiting from Berenberg’s positive analysis. The research office announced on Friday that it had raised bioMérieux from 114.5 to…
bioMérieux: Deutsche Bank initiates purchase coverage
(CercleFinance.com) – Deutsche Bank announced on Tuesday that it had initiated coverage of bioMérieux with a price target of 121 euros, welcoming the group’s flattering track record in terms of…
bioMérieux: what potential?
By Hector Chaunu Published on 04/17/2024 at 12:03 p.m. bioMérieux camped on 101 euros this Wednesday, while Jefferies retains the file with an…
Biomerieux: Praised for its point of activity and its objectives
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
bioMérieux: Oddo BHF raises its price target
(CercleFinance.com) – While maintaining its ‘neutral’ opinion on bioMérieux, Oddo BHF raises its price target from 105 to 113 euros, the day after the presentation of a medium-term roadmap which…
bioMérieux: praised for its point of activity and its objectives – 04/09/2024 at 4:07 p.m.
(CercleFinance.com) – bioMérieux soars by almost 8% after an activity update for the in vitro diagnostics specialist for the first three months of the year, accompanied by the presentation of…
Biomerieux: FDA approval for a multiplex PCR test
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
BioMérieux: FDA approval for a multiplex PCR test
(CercleFinance.com) – BioMérieux announces that it has obtained 510(k) approval and CLIA (Clinical Laboratory Improvement Amendments) waiver from the US Food and Drug Administration (FDA) for its range of rapid…
bioMérieux: boosted by an analyst
By Jean-Baptiste André Published on 03/21/2024 at 3:40 p.m. Photo credit © bioMerieux Company (Boursier.com) — bioMérieux…
bioMerieux is going backwards again…
By Hector Chaunu Published on 03/15/2024 at 11:37 a.m. Photo credit © Biomerieux (Boursier.com) — bioMerieux drops…
bioMérieux: Invest Securities reiterates its opinion – 03/15/2024 at 4:50 p.m.
Member Login Customer Login (CercleFinance.com) – While lowering its price target from 127 to 120 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, ‘an unfairly discounted stock in the…